In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR therapy – saying the results suggested it could offer a "functional cure" for HAE by switching off a gene involved in the potentially life-threatening inflammatory attacks that characterise the disease.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning! Ready for JPM?

Shares of gene editing companies dropped on Friday as Wall Street reacted to Intellia Therapeutics' (NASDAQ:NTLA) plans to lay off 27% of its staff alongside a decision to halt a mid-stage clinical program targeted at a rare genetic disorder.

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development biotech to a commercial-ready company by the end of 2026.